JPRN-UMIN000001119
Completed
Phase 2
Phase II study of the combination of docetaxel, cisplatin plus S-1(DCS) for advanced or recurrent gastric cancer(KDOG 0601) - Phase II study of DCS for advanced gastric cancer
Department of Gastroenterology, Kitasato University School of Medicine0 sites45 target enrollmentStarted: April 14, 2008Last updated:
ConditionsGastric cancer
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Department of Gastroenterology, Kitasato University School of Medicine
- Enrollment
- 45
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients contraindicated to docetaxel,cisplatin,S\-1 2\)Active infection 3\)Severe heart disease 4\)Uncontrolled medical conditions (paralytic ileus,bowel obstruciton,interstitial pneumonia,pulmonary fibrosis,uncontrollable diabetes mellitus,renal failure,liver cirrhosis) 5\)Massive abdominal effusion or massive pleural effusion 6\)Extensive bone metastasis 7\)Symptomatic brain metastasis 8\)Severe diarrhea 9\)Severe mental disorder 10\)Histroy of other active malignancy 11\)Pregnancy, the desire to preserve 12\)Inadequate physical condition, as diagnosed by primary physician
Investigators
Similar Trials
Completed
Not Applicable
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
Unknown
Phase 2
A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.advanced gastric cancerJPRN-UMIN000000801Dept. of Internal Medicine(4)30
Unknown
Phase 2
A Phase II study of docetaxel (T) and cyclophosphamide(C) as adjuvant chemotherapy for patients with high risk, node negative, early stage breast cancerBreast cancerJPRN-UMIN000000493Japan East Cancer Center Breast Cancer Consortium50
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270